Dr. Richard discusses the effects of insufficient GLP-1 activity in Type 2 diabetes and how increased levels of GLP-1 may increase insulin and lower glucose levels.
- Fiasp® (insulin aspart injection) 100 U/mL
- Glucagen® (glucagon) for injection 1 mg/mL
- Levemir® (insulin detemir injection) 100 Units/mL
- Novolin® N (isophane insulin human suspension) 100 U/mL
- Novolin® R (insulin human injection) 100 U/mL
- Novolin® 70/30 (70% human insulin isophane suspension and 30% human insulin injection) 100 U/mL
- NovoLog® (insulin aspart injection) 100 units/mL
- NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection) 100 units/mL
- Ozempic® (semaglutide) injection 0.5 mg or 1 mg
- Tresiba® (insulin degludec injection) 100 units/mL, 200 units/mL
- Victoza® (liraglutide) injection 1.2 mg or 1.8 mg
- Vagifem® (estradiol vaginal inserts) 10 mcg
- Xultophy® 100/3.6 (insulin degludec and liraglutide injection) 100 units/mL and 3.6 mg/mL
- Rybelsus® (semaglutide) tablets 7 mg or 14 mg
- Saxenda® (liraglutide) injection 3 mg
NovoMedLink
For US Health Care Professionals
